Authors
Latest:
Triple Receptor-Negative Breast Cancer: Current and Future TreatmentsBreast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.
Latest:
Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast CancerErika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.
Latest:
Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika HamiltonOncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.
Latest:
Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLCWade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.
Latest:
Pandemic Intensifies the Struggle With Burnout in Cancer FieldThe COVID-19 pandemic has added another burden, with growing evidence of its negative effects on the well-being of many cancer care providers.
Latest:
McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social NeedsThe use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.
Latest:
eContour: Evidence-Based Interactive Contouring Resources at the Point of CareeContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.
Latest:
Clinical Utility of Emerging Molecular Diagnostics in Breast CancerThe past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.
Latest:
Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma TreatmentErin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.
Latest:
Dr. Bertino on the Impact of the EGFR-Mutated Subset Analysis of IMpower150 in NSCLCErin M. Bertino, MD, discusses the impact of the EGFR-mutated subset analysis of the phase 3 IMpower150 trial on the use of immunotherapy in patients with non–small cell lung cancer.
Latest:
Advanced Practice Providers Are Poised to Boost Community Involvement in Clinical TrialsFor those in the community setting, several barriers to clinical research prevent advanced care providers and their patients from taking part in experimental therapies.
Latest:
Erin McMenamin on Head and Neck Cancer TreatmentsErin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.
Latest:
Dr. Murphy on Remaining Questions With SBRT in Pediatric SarcomaErin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.
Latest:
Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric SarcomaErin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.
Latest:
Dr. Hoftstatter on Impact of Molecular Testing on Genetic Abnormalities in Breast CancerErin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.
Latest:
Dr. Seymour on Investigational BTK Inhibitors in CLLErlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.
Latest:
NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion MutationsBefore closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.
Latest:
Dr. Cone on Research Investigating Cardiac Toxicity of GnRH Agonists/Antagonists in Prostate CancerEugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses research investigating the cardiac toxicity of gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer.
Latest:
The Evolving Treatment Landscape of Biliary Tract CancersClosing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Latest:
Dr. Rhee Discusses Workplace Violence in Urology PracticesEugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.
Latest:
Dr Munir on Cost and QOL Outcomes With Zanubrutinib vs Acalabrutinib in B-Cell MalignanciesTalha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.
Latest:
Optimizing Treatment Selection for Patients with FLT3-ITD AMLDiscussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.
Latest:
Dr. Comperat on the Treatment Strategy for Neuroendocrine TumorsEva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).
Latest:
Dr. Goldfischer on Integrated Medical GroupsEvan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.
Latest:
Dr. Evan Alley on KEYNOTE-028 Trial Results in MesotheliomaEvan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.
Latest:
Metastatic Cancer Is a Chronic ConditionAdvancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.
Latest:
Key Takeaways on Updates in Bladder CancerElizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.
